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Abstract
Plaque angiogenesis may have an important role in the development of atherosclerosis. Vasa
vasorum angiogenesis and medial infiltration provides nutrients to the developing and expanding
intima and therefore, may prevent cellular death and contribute to plaque growth and stabilization
in early lesions. However in more advanced plaques, inflammatory cell infiltration, and concomitant
production of numerous pro-angiogenic cytokines may be responsible for induction of
uncontrolled neointimal microvessel proliferation resulting in production of immature and fragile
neovessels similar to that seen in tumour development. These could contribute to development of
an unstable haemorrhagic rupture-prone environment. Increasing evidence has suggested that the
expression of intimal neovessels is directly related to the stage of plaque development, the risk of
plaque rupture, and subsequently, the presence of symptomatic disease, the timing of ischemic
neurological events and myocardial/cerebral infarction. Despite this, there is conflicting evidence
regarding the causal relationship between neovessel expression and plaque thrombosis with some
in vivo experimental models suggesting the contrary and as yet, few direct mediators of
angiogenesis have been identified and associated with plaque instability in vivo.
In recent years, an increasing number of angiogenic therapeutic targets have been proposed in
order to facilitate modulation of neovascularization and its consequences in diseases such as cancer
and macular degeneration. A complete knowledge of the mechanisms responsible for initiation of
adventitial vessel proliferation, their extension into the intimal regions and possible de-novo
synthesis of neovessels following differentiation of bone-marrow-derived stem cells is required in
order to contemplate potential single or combinational anti-angiogenic therapies. In this review, we
will examine the importance of angiogenesis in complicated plaque development, describe the
current knowledge of molecular mechanisms of its initiation and maintenance, and discuss possible
future anti-angiogenic therapies to control plaque stability.
Introduction
According to a World Health Organization Fact Sheet
(EURO/03/06) cardiovascular disease (CVD) is the
number one killer in Europe, with heart disease and
stroke being the major cause of death in all 53 Member
States. Figures show that 34,421 (23% of all non-commu-
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The report also highlighted the fact that there is approxi-
mately a 10-fold difference in premature CVD mortality
between Western Europe and countries in Central and
Eastern Europe with a higher occurrence of CVD amongst
the poor and vulnerable. Although improvements in
understanding have helped to reduce the number of West-
ern European dying from CVD and related diseases fur-
ther advances will require a clearer understanding of the
pathobiological mechanisms responsible for the develop-
ment of stroke, atherosclerosis and myocardial infarction.
Approximately 75% of acute coronary events and 60% of
symptomatic carotid artery disease are associated with dis-
ruption of atherosclerotic plaques [1]. In 1971, Folkman
[2]introduced the concept of angiogenesis as a necessity for
tumour growth. Its importance in other pathological conditions,
including, atherosclerosis, myocardial infarction and stroke was
later realized [3,4]. Angiogenesis is the formation of new
blood vessels from a pre-existing vascular network, and is
an important phenomenon in physiological situations
such as embryonic development and wound healing as
well as in pathological conditions like diabetic retinopa-
thy, rheumatoid arthritis, tumor progression and athero-
sclerosis. Endothelial cells (EC) which line the inside of
blood vessels are the target cells of angiogenic regulators.
Stimulated EC undergo metabolic modifications associ-
ated with the main steps of angiogenesis i.e. production of
matrix metalloproteinases that degrade the basement
membrane and extracellular matrix (ECM); stimulation of
EC migration and proliferation; secretion of collagen and
differentiation resulting in sprout formation and ulti-
mately, formation of new blood vessels [3,5].
Angiogenesis in cardio- and cerebrovascular disease: 
Evidence for it as a major determinant of plaque growth, 
instability and rupture
Histological characteristics of plaque angiogenesis
In normal arteries, adventitial blood vessels originating
from the vasa vasorum penetrate into the vessel wall at
regular intervals and bifurcate around the circumference
of the artery. They don't extend beyond the outer media,
and diffusion of oxygen and nutrients is limited to
approximately 100 μm from the vessel lumen [6]. Angio-
genesis is a recognized feature of the atherogenic process
in both coronary and carotid disease, intimal neovascular-
ization arising frequently following activation and prolif-
eration of the dense network of vessels in the adventitia
adjacent to a plaque [7]. New vasa vasorum (VV) have
been identified in developing lesions and these invade the
intima at specific sites of medial disruption, whilst the
intima and media of complicated plaques in coronary
atherosclerotic vessels have been shown to be infiltrated
with a tumor-like mass of microvessels which are prone to
leak [8]. These angiogenic blood vessels have been identi-
fied in complicated regions of human aortic lesions fol-
lowing immuno-staining with antibodies to CD105
(endoglin; which binds only to active endothelial cells)
and transforming growth factor-beta 1 (TGFβ-1) [9].
Immature neovessels are most often localized in regions
of inflammatory/macrophage cell infiltration (and less
common in highly calcified or hyalinized plaques) and at
the shoulders of thin-cap atheromas prone to rupture
[10]. In a study of coronary artery atherogenesis, lesions
were examined from coronary arteries from excised hearts
of patients. The highest neovessel content was demon-
strated in type VI plaques and this was associated with the
highest rate of thrombotic episodes [11], whilst other
post-mortem studies showed approximate increases in
vessel density of twofold in vulnerable plaques and four-
fold in disrupted plaques compared with severely
obstructed but stable lesions [12]. Similarly, increased
angiogenesis and angiogenic gene expression measured
using microarrays, together with significantly thinner
plaque fibrous caps was associated with symptomatic
carotid atherosclerosis [13].
Some earlier studies failed to identify a direct relationship
between plaque angiogenesis and instability and direct
evidence for the contribution of VV proliferation and/or
intimal neovascularization as a cause of plaque rupture is
still limited. Part of the reason for this may have been the
lack of suitability and similarity between experimental
models of atherosclerosis designed using small mammals,
which often produce small plaques with limited neovas-
cularization, possibly due to the much smaller diameter
of the vessels and media thickness, compared with human
vessels and hence many people do not believe they can be
used reliably to predict development of unstable lesions
in humans [for a review see, [14]]. Several patient studies
also demonstrated that plaque haemorrhage in human
coronary atherosclerosis was not always a feature of inti-
mal areas with high microvessel density [15], whilst inti-
mal microvessels were only detected in 64% of restenotic
human coronary atherosclerotic specimens [16]. How-
ever, although the presence of a vascular cell neointimal
region is not a prerequisite for unstable plaque develop-
ment, overwhelming evidence now points to this process
as being a key instigator of plaque fragility leading to rup-
ture. Various studies have demonstrated a clear associa-
tion between VV activation and neointimal formation. In
animal models, VV angiogenesis enhanced neointima for-
mation in both the rabbit collar and rat angioplasty mod-
els of carotid artery injury, whilst perivascular adenoviral
gene transfer of dominant negative FGFR-1 significantly
attenuated VV angiogenesis in response to injury [17].
Further evidence is supplied below:Page 2 of 10
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are features of angiogenic neovessels
The irregular nature of blood vessel formation, and its
similarity to tumor angiogenesis, suggests that the factors
responsible for their growth may be different from those
seen during normal wound healing. Newer technological
approaches have been able to discriminate between local-
ised micro-environments in individual neointimas using
antibodies directed to proteins expressed in actively grow-
ing vessels. These studies showed the presence of areas of
mature vessel development where haemorrhage was
absent as opposed to those containing irregular immature
and highly angiogenic vessels where haemorrhage was
taking place, and which may help to explain these earlier
contadictory findings. For example, Dunmore et al, [18],
demonstrated that irregular dysmorphic heamorrhagic
vessels without smooth muscle cell coatings, were almost
exclusively found in plaques from patients with sympto-
matic carotid artery disease. Furthermore, these single-
layer endothelial tubes co-localized specifically with
pockets of VEGF expression providing strong support for
the idea that proliferating immature neovessels may be
associated with plaque instability and rupture. Similarly,
haemorrhagic, leaky blood vessels from unstable carotid
plaques proliferate abnormally, and although of relatively
large caliber remained immature by virtue of a poor
investment with smooth muscle cells and pericytes. These
vessels also possessed structural weaknesses with poorly
formed EC junctions that may also contribute to instabil-
ity of the plaque by facilitation of inflammatory cell infil-
tration and haemorrhagic complications [19], (Figure 1;
[20]). In vivo studies showed a strong correlation between
areas of increased vascularity, intraplaque haemorrhage
and neurological events defined by CT, with subsequent
histological staining using anti-CD34 antibodies visualiz-
ing EC of the vessels in symptomatic patients following
endarterectomy [21].
Intraplaque haemorrhage results in rapid expansion of the
plaque necrotic core, due to the fact that red blood cell
membranes are a rich source of free cholesterol and phos-
pholipids and the process occurs in association with
excessive macrophage infiltration [22]. The size of the
necrotic core directly correlates with the risk of plaque
rupture. Furthermore, intraplaque haemorrhage and
plaque rupture were proportional to neovessel density in
coronary atheroma [23]. Adventitial vessels in unstable
plaques contain perivascular smooth muscle cells, how-
ever, after plaque rupture, the fibrous cap is disrupted
with a luminal thrombus and the newer branches of vasa
vasorum close to the necrotic core consist almost entirely
of a single layer of EC overlying a ruptured, leaky base-
ment membrane, and associated with remnants of red
blood cells [24]. Defects are thought to be caused by pro-
teolytic damage from on-going inflammation and release
of signalling molecules affecting cell-cell contact.
Relationship between inflammation and angiogenesis in 
promotion of plaque development?
The atherosclerotic process is often initiated before adult-
hood, when cholesterol-containing low-density lipopro-
teins accumulate in the intima and activate the
endothelium. Leukocyte adhesion molecules and chem-
okines promote recruitment of monocytes and T cells.
Monocytes can differentiate into macrophages and up-
regulate pattern recognition receptors, including scaven-
ger receptors and toll-like receptors. Scavenger receptors
mediate lipoprotein internalization, which leads to foam-
cell formation. Toll-like receptors transmit activating sig-
nals that lead to the release of cytokines, proteases, and
vasoactive molecules, and are considered to be an impor-
tant link between inflammation and cardiovascular dis-
ease [25]. Deficiency of toll-like receptor 4 (TLR-4)
protein leads to a reduction in macrophage recruitment in
A-B) CD105 positive neovessels in a grade V carotid plaque from a patient who had undergone end rtere tomyFigure 1
A-B) CD105 positive neovessels in a grade V carotid 
plaque from a patient who had undergone endarter-
ectomy. Grading was based on the classification of Stary 
[67]; lipid containing plaques with evidence of inflammation 
and angiogenesis) Only selected microvessels are CD105 
positive in these lesions suggesting a dynamic feature of ang-
iogenesis within the plaque architecture. A is × 40 and B × 
100. C) Shows expression of immature neointimal vessels 
composed of only endothelial cell lining and stained positive 
for CD105 (black arrows), in contrast to more mature ves-
sels negative for CD105 and possessing a smooth muscle cell 
coating (red arrows) Photomicrographs are × 100. D) Shows 
morphologically distinct multilobulated abnormally develop-
ing vessels again, stained positive for CD105 without smooth 
muscle cell or pericyte involvement in the neointima of a 
grade V plaque (× 100).Page 3 of 10
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[26]. T cells in lesions recognize local antigens and mount
T helper-1 responses with secretion of pro-inflammatory
cytokines that contribute to local inflammation and
growth of the plaque [27].
VV density, their proliferation and medial-intimal infiltra-
tion, and concurrent adventitial inflammation are
strongly associated with advanced lesions [28]. Plaque
neovascularization correlated with the extent of inflam-
mation in hypercholesterolemic apoE mice and inhibi-
tion of vessel formation reduced macrophage
accumulation and plaque progression [22]. Similarly,
transfection with murine soluble VEGF-R1 inhibited early
inflammation and late neointimal formation, again sug-
gesting that as neovessels are generated, so the inflamma-
tory response is perpetuated in a continuous cycle [29].
Inflammatory infiltrates enhance recruitment of mono-
cytes, secrete matrix metalloproteinases and increase the
expression of γ-interferon (from t-lymphocytes) which
may weaken the fibrous cap; similarly, they can induce
synthesis of angiogenic tissue angiotensin-converting
enzyme, growth factors, interleukin-8 and tissue factor
[15]. The importance of the inflammatory response was
demonstrated in vivo where oral treatment of apoE-/LDL-
double knockout mice with the anti-inflammatory com-
pound 3-deazaadenosine prevented lesion formation
[30]. A strong correlation has been shown between mac-
rophage infiltration, intraplaque haemorrhage and rup-
ture-prone thin-cap lesions with high microvessel density,
whilst these features are not common in calcified or hya-
linized human arterial plaques, suggesting a strong link
between neovascularization, inflammation and thrombo-
sis [15,31]. The phenotype of plaque neovessels could
also be important in determining plaque stability, for
example, new vascular networks, and immature vessels
with poor integrity and no smooth muscle cell/pericyte
coverage would likely act as sites for inflammatory cell
infiltration, inflammatory cell leakage and intraplaque
haemorrhage respectively [22]. The correlation of focal
collections of inflammatory cells with areas of intraplaque
neovascularization and haemorrhage, suggests that
release of growth factors and cytokines by macrophages
and leukocytes may have a key role in modulating the vas-
cularization process [8]. Evidence for the existence of
hotspots or "neovascular milieu" was found in lesions
from ApoE-/- mice where the density of VV was highly cor-
related with the presence of inflammatory cells rather
than plaque size, whilst deposition of RBC membranes
within the necrotic core of plaques also leads to an
increase in macrophage infiltration and therefore may fur-
ther potentiate the inflammatory response [22,23].
Hypercholesterolaemia may be associated with prolifera-
tion of VV in coronary and carotid vessels at early stages of
plaque development. Williams JK [32] first demonstrated
that the presence of atherosclerosis in hypercholestero-
lemic monkeys induced an increase in blood flow
through the VV and plaque regression caused by removal
of the high lipid diet reduced the VV concentration and
blood flow to the coronary media and intima. High cho-
lesterol levels are associated with increased serum VEGF
expression and may cause up-regulation of growth factor
receptors on both endothelial and smooth muscle cells
[33]. Furthermore, oxidized LDL (ox-LDL) generated in
response to pro-oxidative cellular changes can exacerbate
the inflammatory response, since engulfment of intact
apoptotic cells was reduced in the presence of ox-LDL and
in its absence, rapid phagocytosis suppressed macrophage
inflammatory cytokine release, suggesting a link between
high lipid levels, inflammation and possibly angiogenesis
[33]. In vitro studies have demonstrated that stimulation
of HUVEC with ox-LDL up-regulates adhesion molecules
(including ICAM-1, E-selectin and P-selectin), inflamma-
tory proteins including Il-6, thrombotic factors including
tissue factor and remodeling proteins such as MMP-2 and
MMP-9, many of which are also stimulators of angiogen-
esis [34].
Medial and intimal thickening induced by hypercholeste-
rolemia may result in a limited supply of oxygen and
nutrients reaching these areas from either the lumen and/
or VV, resulting in a hypoxic environment. Since the
major outcome of hypoxia is increased vascularization,
intraplaque vessels may proliferate in association with
this potent stimulus. Hypoxia-inducible factor (HIF-1) is
expressed in hypoxic regions of expanding and develop-
ing plaques, and directs migration of EC towards the
hypoxic environment via direct HIF-1 binding the regula-
tory gene of VEGF and subsequent induction of VEGF
transcription [35]. VEGF is a potent angiogenic growth
factor, stimulating EC mitogenesis and blood vessel for-
mation via activation of intracellular signalling intermedi-
ates including mitogen-activated protein kinase 1/2
(MAPK1/2) and src. Increased expression of VEGF and its
receptors in hypoxic areas, in association with interaction
with cell membrane integrins including α5β3, is one of the
main causes of vessel leakiness [36]. Leaky plaque VV have
been identified by ultrastructural visualization of defects
between endothelial tight, gap and adherens junctions,
and VEGF is known to affect junctional adhesion mole-
cule expression, block gap junctional communication
between adjacent endothelial cells and disrupt tight junc-
tional communication through a src-dependent pathway
[37].
Oxidized phospholipids such as 1-palmitoyl-2-arachido-
noyl-sn-glycero-3-phosphorylcholine (Ox-PAPC), also
prevalent in atherosclerotic lesions, can also up-regulate
VEGF expression. In addition, they can regulate leukocyte-Page 4 of 10
(page number not for citation purposes)
Journal of Angiogenesis Research 2009, 1:4 http://www.jangiogenesis.com/content/1/1/4endothelial cell interactions and induce expression of
inflammatory cytokines from local endothelial cells,
monocytes and macrophages [38].
In vivo evidence for modified expression of pro/anti-angiogenic 
molecules in high grade plaques
In the quiescent state, VV of normal arteries provide nutri-
ents to the tunica media whilst the intima is fed by oxygen
diffusion from the lumen. The VV remains in a dormant
state probably due to the expression and synthesis of anti-
angiogenic factors e.g. thrombospondin and endostatin
which more than counterbalance the presence of low
quantities of pro-angiogenic factors in the micro-environ-
ment [39]. However during intimal plaque development,
the balance between the angiogenic and anti-angiogenic
factors may become altered with increased production of
growth factors and cytokines together with a reduction in
negative modulators resulting in adventitial vessel angio-
genesis at the site proximal to internal vascular damage
and plaque growth [40]. Hence the angiogenic switch
shifts to on.
Key molecules involved in initiation and/or maintenance
of the angiogenic process, and which may prove to be
potential therapeutic targets of modulation include the
angiopoietin-Tie signaling pathways. Ang-1 and -2 are lig-
ands of the endothelial receptor Tie-2. Ang-1 via Tie-2
binding induces formation of stable blood vessels,
whereas Ang-2 destabilizes the interaction between EC
and their support cells [41]. In a recent study by Post et al
[42], a positive correlation was observed between the ratio
of expression of Ang-1/Ang-2, the macrophage count and
mean vessel density in complicated fibroatheromatous
carotid human plaques. Ang-2 also correlated with the
activity of matrix metalloproteinase-2 (MMP-2) expres-
sion suggesting a role in development of unstable plaque
microvessels. Tie-2 is a tyrosine kinase receptor expressed
predominantly on EC, and which has been shown to acti-
vate intracellular signal transduction through Akt and
ERK1/2 following ligand binding of angiopoietin-1 result-
ing in angiogenesis both in vitro and in vivo. In relation
to tumour neovascularization, expression of Tie-2 was
concentrated in vascular hot-spots at the leading edge of
invading tissue [43]. Furthermore, Ang-1 is an anti-
inflammatory cytokine which can reduce neovessel leak-
age and vascular permeability partly via inhibition of cell
membrane adhesion molecule expression, whilst an
increase in Tie-2 together with increased availability of
Ang-1 may enhance neointimal vascularization and pro-
mote formation of stable vessels less prone to haemor-
rhage [44]. Placental growth factor (PIGF), a member of
the VEGF family, binds to the Flt-1 receptor, is a mediator
of inflammation and is highly expressed in atherosclero-
sis, correlating with both levels of plaque inflammation
and microvascular density in symptomatic patients with
carotid plaques [45]. Many other pro-angiogenic factors
have been demonstrated to be present in neointimal
lesions although direct evidence for their involvement in
mediating vascularization in vivo is still lacking and hence
they have not been described in this review. Worthy of
note, however, is the work of Leroyer et al [46] showing
that atherosclerotic plaques contained a large number of
membrane-shed microparticles originating from the
breakdown of apoptotic macrophages. Isolated micropar-
ticles were highly angiogenic both in vitro and in vivo and
those obtained from symptomatic patients expressed
more CD40L and were more potent in mediation of ang-
iogenesis which was blocked in the presence of CD40-
neutralising antibodies, suggesting a novel mechanism for
stimulation of plaque neovascularization.
Key inhibitors of angiogenesis may be reduced in areas
undergoing neovascularization and the balance of pro-
angiogenic and anti-angiogenic molecule expression
shifts towards blood vessel formation. Thrombospondin-
1 (TSP-1) has been implicated in development of vascular
diabetic complications and is expressed in developing
arterial plaques [47]. Platelet factor IV is expressed by
active platelets in plaques [48], whilst increased expres-
sion of Collagen XVIII and its proteolytically released
endostatin fragment is associated with inhibition of ang-
iogenesis in the vascular wall, and it has been shown that
ApoE knockout collagen XVIII minus animals developed
significantly more vasa vasorum than wild type [39]. T-
cadherin, is involved in maintenance of vascular integrity
and growth, is up-regulated in developing atherosclerotic
lesions. The effect of T-cadherin on angiogenesis in vivo
was evaluated in detail by Rubina et al, [49] using a
Matrigel implant model. They demonstrated that T-cad-
herin over-expression in L929 cells injected in Matrigel
inhibited neovascularization of the plug. In vitro, T-cad-
herin inhibited the directional migration of endothelial
cells, capillary growth, and tube formation but had no
effect on endothelial cell proliferation, adhesion, or apop-
tosis.
Pharmacological inhibition of VV angiogenesis inhibits 
plaque development and instability in vivo models of 
atherosclerosis
In vivo studies showed that blocking blood vessel forma-
tion can significantly reduce plaque size. Moulton et al,
[50] demonstrated that two potent angiogenesis inhibi-
tors, endostatin and TNP-470 were able to reduce neoves-
sel formation and concomitant aortic plaque growth in
apolipoprotein E (ApoE)-deficient mice. Recently, Stefa-
nadis et al, [51], showed that treatment of New Zealand
rabbits under atherogenic diet, with antibodies specific
for VEGF, resulted in significant reduction in neovessel
growth and neointimal thickness after four weeks. Simi-
larly, Gossl et al, [52] showed that inhibition of VV neo-Page 5 of 10
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swine using thalidomide, significantly reduced neointi-
mal plaque formation and intima-media thickness. The
same authors also demonstrated that areas of the coronary
vascular wall with low density of VV were most suscepti-
ble to microinflammation, hypoxia and oxidative stress
making them most likely the starting points of early
atherogenesis [53]. Similarly, Drinane et al [54] showed
that treatment of LDLR(-/-) ApoB-48-deficient mice with
an anti-angiogenic truncated form of plasminogen activa-
tor inhibitor (PAI) inhibited VV growth through a mecha-
nism involving FGF-2 and resulted in reduced plaque
development. Reduced blood flow to the end branches of
the VV as seen in patients with vascular risk factors could
lead to inflammation followed by increased permeability,
LDL-lipoprotein up-take and macrophage phagocytosis
leading to foam cell formation [55]. These results suggest
that anti-angiogenic therapy may have beneficial effects in
patients by modulating plaque vascularization. Whilst it is
important to have normal healthy functional VV, preven-
tion of their proliferation could represent the first stage of
therapy against atherosclerotic plaque formation.
Identification of a blueprint for the angiogenic switch-future 
treatment perspectives
Atherosclerosis is a chronic inflammatory disorder, and
angiogenesis plays a complex role in atherothrombosis. In
addition it is recognized that during plaque development
many pro-angiogenic pathways are re-activated and this
leads to formation of immature blood vessels prone to
rupture. Therefore, inhibition of angiogenesis might be an
important target to prevent the development of active,
unstable plaque lesions. Identification of pathophysiologi-
cal changes related to angiogenesis may lead in future to
design of novel treatments for inhibition of plaque develop-
ment.
In vascular plaques, abnormally behaving cells are sur-
rounded by heterogeneous tissue elements, such that the
areas of interest/diseased cells may constitute less than 5%
of the volume of a tissue biopsy specimen and also may
consist of dynamic micro-hotspots which are difficult to
analyse in great detail using conventional dissection and
non-quantitative global gene or protein microarrays.
Hence, techniques such as laser-capture micro-dissection
for isolation of specific microvessels in both the VV and
intima of evolving lesions could help to identify both the
genetic fingerprints associated with blood vessel activa-
tion and stimulatory factors associated with the surround-
ing inflammatory micro-areas in complicated unstable
plaque regions. This technique has been used previously
successfully by Roy et al, [56] who compared global gene
expression between blood vessels isolated by laser-capture
from normal skin and identified important de-regulated
genes including heparin sulphate 6-O-endosulphatase1
(anti-angiogenic) and a reduction in CD24 (angiogenic)
in vessels isolated from within chronic wounded tissue.
Our recent un-published work employing Real-time PCr,
TaqMan angiogenesis-directed microarrays has demon-
strated concurrent over-expression of NOTCH-3/DLL4
and Ang-1/Tie-2 proteins as well as KDR, HBEGF and
RAGE in the same microvessels from micro-dissected ang-
iogenic (CD105-positive) vessels from unstable human
endarterectomy specimens, whilst these proteins were
weakly expressed or not expressed in the same lesion/sec-
tion in an area containing stable inactive vessels, suggest-
ing a complex but specifically localized activation and
signaling cascade is involved in mediating vascularization
in growing neointimal lesions. This suggests that actively
growing neovessels are re-expressing these embryologi-
cally derived genes which have been shown to regulate
formation of tip cells during angiogenesis, and therefore
may form part of an attempt to regulate formation of sta-
ble vessels which could be less prone to leakage [57].
Since inhibition of Notch signalling has been shown to
increase the total number of vessels in solid tumour mod-
els but reduce the patency and vascular function of the
remaining vessels (resulting in "chaotic" vessels), it may
have similar effects on neointimal vessels and supplemen-
tation could be considered as part of a therapeutic pro-
gramme of normalization and stabilization of existing
vasculature promoting plaque stability. Some of the cur-
rent research is directed to endothelial progenitor cells.
They appear to be mobilized from the bone marrow by
angiogenic factors to the adventitial space, and recent
studies have shown that progenitor cells in the adventitia
can contribute to progression of atherosclerosis, and EPC
concentrations were significantly associated with severity
and presence of multivessel coronary artery disease [58].
It is possible that these progenitor cells may be involved
in development of new vasa as well as neointimal leaky
vessels and therefore future therapeutics might also con-
sider methods to restrict their differentiation in ang-
iogenic microenvironments of developing plaques.
Knowledge of which factors are expressed and at what times
during plaque development may help in the design of a new
therapeutic approach to target multiple mediators at differ-
ent time windows during plaque development.
Accurate identification of VV susceptible to development
of hypoxic microenvirnments is likely to become a possi-
bility in the next few years with the development of con-
trast-enhanced and targeted ultrasound imaging
(Magnoni et al, 2009; Granada et al, 2008) [59,60]. Aden-
oviral delivery of genes, directed against angiogenic mole-
cules, to the perivascular surface of these VV in order to
inhibit their proliferation would represent a first line of
attack, whilst pharmacological treatments to reduce stem
cell differentiation and/or reduce local inflammation andPage 6 of 10
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future combinational therapies [[61]; Figure 2]. Weak
neovascular beds in plaque intima as well as activated
adventitial blood vessels are potential targets for molecu-
lar imaging and targeted drug therapy, however, the
majority of potential imaging and therapeutic agents have
been unsuccessful because of their limited capacity to
reach and remain stably within the target tissue or cells in
vivo. The idea of using peri-vascular combinational gene
therapy for inhibition of VV activation was mentioned in
an earlier section. Advantages of this outside-in mecha-
nism is that the integrity of the vessel wall would remain
intact and high concentrations of gene delivery vectors
can be retained in the local environment, producing min-
imal inflammatory reaction, when compared with current
systemic therapies [62].
Molecular imaging for the visualization of vulnerable
atherosclerotic plaques may be useful in detecting
patients at risk of thrombosis and by recognition of indi-
vidual cellular and molecular characteristics, provide the
potential for offering personalized medical treatment. For
example, when large numbers of paramagnetic gadolin-
ium complexes (>50,000) are incorporated onto emul-
sion particles, the signal enhancement for each binding
site is magnified dramatically compared with conven-
tional contrast reagents [[63] and references therein].
Neovessels in coronary plaques of cholesterol-fed apoE
mice have been imaged using vascular cell adhesion mol-
ecule-1 peptide sequence (VHSPNKK) bound to cross-
linked magneto-fluorescent super-paramagnetic iron
oxide (CLIO) particles. The particles were shown to selec-
tively bind to aortic plaque vasculature 24 h after injection
Hypothetical representation of a micro-area of a major artery showing vasa vasorum and potential hypoxic micro-environment res nsible for cellular activation, endoth lial cell pr life ation and ultimately plaque devel pmentFigure 2
Hypothetical representation of a micro-area of a major artery showing vasa vasorum and potential hypoxic 
micro-environment responsible for cellular activation, endothelial cell proliferation and ultimately plaque 
development. Phase 1 treatment may involve prevention of vasa vasorum proliferation by administration of targeted siRNA 
to block relevant gene expression. In patients with existing high grade atherosclerotic plaques, the neointima often presents 
with microvessels of differing levels of maturity and stability/patency. Phase 2 treatments would be designed to induce stabiliza-
tion of vessels liable to rupture and bleed by administrating a mixture of factors to induce maturation of fragile vessels. Vascu-
larization in atherosclerosis represents a complex interaction between multiple molecules, manipulation of which could benefit 
patients by slowing down the process of atherosclerosis and stabilizing existing plaques.
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ogy and fluorescent analysis of tissue samples performed
after euthanasia, suggesting potential diagnostic and ther-
apeutic applications [64]. In humans, contrast-enhanced
carotid ultrasound imaging was able to identify intra-
plaque neovascularization which correlated with later his-
tological findings employing the use of antibodies
directed to CD31 and CD34 for identification of the ves-
sels [65]. Similarly, α5β3 integrin targeted perfluorocarbon
nanoparticles have been successfully used to detect neo-
vasculature in a rabbit model of aortic valve disease sug-
gesting a potential application in humans. In addition,
the same technology could be used to home to angiogenic
areas or microenvironments, and release targeted knock-
out genes in order to block VV proliferation, and thereby
reduce neointimal expansion or to inhibit neointimal
angiogenesis directly or maturate existing fragile rupture-
prone vessels. It is important to remember that bioactive
molecules of the extracellular matrix including proteogly-
cans such as hyaluronan whose turnover as regulated by
growth factors such as transforming growth factor-β and
proteases including matrix metalloproteinases, would
also be considered potential therapeutic targets for con-
trolling the angiogenic switch in specific susceptible
microenvironments [66]. Anti-angiogenic agents have
previously been shown to "prune" tumour vessels and
normalize the structure of remaining vessels and therefore
might help to stabilize rupture-prone plaques via a similar
mechanism [67]. In relation to the process of angiogen-
esis, fragile endothelial cells of angiogenic neovessels
express specific markers such as α5β3 integrin, CD105
receptors VEGF-R2 and/or apelin [68], which could be
used in this targeting protocol.
Conclusion
Current imaging methodologies may be used in conjunc-
tion with emerging therapies based on the use of angio-
genesis-targeted nanoparticles which will allow both the
identification and tracking of drugs and also prove to be
more effective for the delivery of drugs to target sites. The
preferential aim would be to prevent initial development
of neointimal vascular sites by blocking adventitial blood
vessel activation in patients with low grade plaques might
represent 1) future imaging targets able to identify
patients developing unstable plaque regions susceptible
to rupture, and 2) prevent or slow down development of
atheroma thereby improving treatment and survival rates
of patients with a history of development of myocardial
infarction or ischaemic stroke.
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